PT  - JOURNAL ARTICLE
AU  - Arvind Manoharan
AU  - William Anderson
AU  - Brian Lipworth
TI  - Influence of β2-adrenergic receptor polymorphism on methacholine hyperresponsiveness in asthmatic patients
DP  - 2013 Sep 01
TA  - European Respiratory Journal
PG  - P1396
VI  - 42
IP  - Suppl 57
4099  - http://erj.ersjournals.com/content/42/Suppl_57/P1396.short
4100  - http://erj.ersjournals.com/content/42/Suppl_57/P1396.full
SO  - Eur Respir J2013 Sep 01; 42
AB  - Introduction and background: We previously reported that the β2-adrenergic receptor (ADRB2) polymorphism had no effect on bronchial hyperresponsiveness (BHR) to methacholine in asthmatic patients (Wilson, AM et al Allergy. 2006; 61:254-259). We have now replicated this analysis in a different and larger cohort of patients.Aims and objectives: To assess the effect of the ADRB2 polymorphism in methacholine-responsive patients with asthma.Methods: We conducted a retrospective analysis of the effects of ADRB2 haplotypes at position 16 (Gly/Arg) and 27(Gln/Glu) in 449 patients with a physician diagnosis of asthma who were responsive to methacholine (ie, provocation concentration that caused a decrease in FEV1 of 20% [PC20], <8 mg/mL).Results: No differences were found in age, FEV1, or inhaled corticosteroid dose among the genotypes or haplotypes. No significant differences were found in methacholine PC20 between the separate genotypes at position 16 or 27 or between the haplotypes at positions 16/27 combined.View this table:Table 1: Methacholine PC20 according to haplotypeConclusions: We have confirmed in this replication study that common ADRB2 genotypes or haplotypes at positions 16/27 do not influence BHR in methacholine-responsive patients with asthma.